Mettez-vous hors ligne avec l'application Player FM !
E25-RIVAL Study: Ranibizumab vs Aflibercept in T&E for wet AMD- Dr. Mark Gillies
Manage episode 231808632 series 2416620
Dr. Mark Gillies from Sydney, Australia discusses 2-year results of the RIVAL Study which investigated rates of geographic atrophy and visual acuity changes in patients with wet AMD.
Full reference:
Gillies, M. C., Hunyor, A. P., Arnold, J. J., Guymer, R. H., Wolf, S., Ng, P., . . . McAllister, I. L. (2019). Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.6776
83 episodes
Manage episode 231808632 series 2416620
Dr. Mark Gillies from Sydney, Australia discusses 2-year results of the RIVAL Study which investigated rates of geographic atrophy and visual acuity changes in patients with wet AMD.
Full reference:
Gillies, M. C., Hunyor, A. P., Arnold, J. J., Guymer, R. H., Wolf, S., Ng, P., . . . McAllister, I. L. (2019). Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.6776
83 episodes
Tous les épisodes
×Bienvenue sur Lecteur FM!
Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.